Positions

Overview

  • 2/2001-11/2004 Postdoctoral Fellow, Department Molecular Pathology, The University of Texas, M. D. Anderson Cancer Center, Houston, TX (Dr. Kun-Sang Chang)

    12/2004-11/2009 Assistant Professor (Research), Department of Molecular Therapeutics (Department of Systems Biology), The University of Texas M. D. Anderson Cancer Center, Houston, TX.

    11/2009-present Assistant Professor (tenure track), Division of Hematology / Oncology & Comprehensive Cancer Center, The University of Alabama at Birmingham, Birmingham, AL
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 Inhibitor of growth 4 affects hypoxia-induced migration and angiogenesis regulation in retinal pigment epithelial cellsJournal of Cellular Physiology.  234:15243-15256. 2019
    2019 Notch1 inhibition enhances DNA damage induced by cisplatin in cervical cancerExperimental Cell Research.  376:27-38. 2019
    2019 Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven MelanomagenesisCell.  176:1113-1127.e16. 2019
    2019 Recent findings in the regulation of programmed death ligand 1 expressionFrontiers in Immunology.  10. 2019
    2018 The protective role of DOT1L in UV-induced melanomagenesisNature Communications.  9. 2018
    2018 Targeting the upstream transcriptional activator of PD-L1 as an alternative strategy in melanoma therapyOncogene.  37:4941-4954. 2018
    2018 Piperlongumine and p53-reactivator APR-246 selectively induce cell death in HNSCC by targeting GSTP1Oncogene.  37:3384-3398. 2018
    2018 AMP-activated protein kinase protects against necroptosis via regulation of Keap1-PGAM5 complexInternational Journal of Cardiology.  259:153-162. 2018
    2018 PARP-1 inhibitors sensitize HNSCC cells to APR-246 by inactivation of thioredoxin reductase 1 (TrxR1) and promotion of ROS accumulationOncotarget.  9:1885-1897. 2018
    2017 Focal Adhesion Kinase Regulates Hepatic Stellate Cell Activation and Liver FibrosisScientific Reports.  7. 2017
    2017 Palmitoylation-dependent activation of MC1R prevents melanomagenesisNature.  549:399-403. 2017
    2017 Over-expression of BAG-1 in head and neck squamous cell carcinomas (HNSCC) is associated with cisplatin-resistanceJournal of Translational Medicine.  15. 2017
    2017 LKB1 inhibits HPV-associated cancer progression by targeting cellular metabolismOncogene.  36:1245-1255. 2017
    2017 Celastrol induces apoptosis in hepatocellular carcinoma cells via targeting ER-stress/UPROncotarget.  8:93039-93050. 2017
    2016 O-linked GlcNAcylation elevated by HPV E6 mediates viral oncogenesisProceedings of the National Academy of Sciences.  113:9333-9338. 2016
    2016 Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)Autophagy.  12:1-222. 2016
    2016 Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356Autophagy.  12:443. 2016
    2016 LKB1 is a DNA damage response protein that regulates cellular sensitivity to PARP inhibitorsOncotarget.  7:73389-73401. 2016
    2015 The E3 ligase APC/CCdh1 promotes ubiquitylation-mediated proteolysis of PAX3 to suppress melanocyte proliferation and melanoma growthScience Signaling.  8. 2015
    2015 Myristoylation confers noncanonical AMPK functions in autophagy selectivity and mitochondrial surveillanceNature Communications.  6. 2015
    2015 LKB1 reduces ROS-mediated cell damage via activation of p38Oncogene.  34:3848-3859. 2015
    2015 Recent advances in the study of HPV-associated carcinogenesisVirologica Sinica.  30:101-106. 2015
    2015 Induction of BCL2-interacting killer, BIK, is mediated for anti-cancer activity of curcumin in human head and neck squamous cell carcinoma cellsJournal of Cancer.  6:327-332. 2015
    2015 The tissue dependent interactions between p53 and Bcl-2 in vivoOncotarget.  6:35699-35709. 2015
    2014 Activity of CEP-9722, a poly (ADP-ribose) polymerase inhibitor, in urothelial carcinoma correlates inversely with homologous recombination repair response to DNA damageAnti-Cancer Drugs.  25:878-886. 2014
    2014 Liver kinase B1 regulates the centrosome via PLK1Cell Death and Disease.  5. 2014
    2014 MIR106B and MIR93 prevent removal of bacteria from epithelial cells by disrupting ATG16L1-mediated autophagyGastroenterology.  146:188-199. 2014
    2014 Targeting the LKB1 tumor suppressorCurrent Drug Targets.  15:32-52. 2014
    2013 Piperlongumine induces autophagy by targeting p38 signalingCell Death and Disease.  4. 2013
    2013 Stat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomasJournal of Investigative Dermatology.  133:2041-2049. 2013
    2013 TBX2 expression is regulated by PAX3 in the melanocyte lineagePigment Cell Research.  26:67-77. 2013
    2012 Metformin impairs the growth of liver kinase B1-intact cervical cancer cellsGynecologic Oncology.  127:249-255. 2012
    2012 FGF2 regulates melanocytes viability through the STAT3-transactivated PAX3 transcriptionCell Death and Differentiation.  19:616-622. 2012
    2010 Natural triterpenoid avicins selectively induce tumor cell deathCommunicative and Integrative Biology.  3:205-208. 2010

    Research Overview

  • The objectives in Dr. Xu's lab are to identify the molecular mechanisms underlying tumor suppressor function and to develop pharmacological agents that can modulate or mimic tumor suppressors for cancer prevention and treatment. Specifically, the lab currently has three research directions:
    (1) Tumor suppressor and genomic stability: (A) To investigate mechanisms of how tumor suppressors, such as LKB1 (also known as serine/threonine kinase 11, STK11), PML, and p53, regulate genomic stability; (B) To determine LKB1-related protein signatures and signaling networks under stressed conditions and identify novel LKB1-interacting proteins; (C) To define LKB1 expression (mutation) in tumors and its relationship to patient outcomes and therapeutic response.
    (2) Cell death---Autophagy and Necrosis: (A) To determine the role of autophagy in LKB1-mediated genomic stabilization; (B) To screen and characterize genes that regulate autophagy and necrosis in mammalian cells; (C) To determine the role of autophagy and necrosis in tumorigenesis and targeted therapy.
    (3) Molecular therapeutics: To develop pharmacologic agents targeting the LKB1-AMPK-mTOR pathway for cancer prevention and treatment.
  • Investigator On

    Education And Training

  • Doctor of Philosophy in Oncology and Cancer Biology, Soochow University 2000
  • Master of Science in Physiology, Pathology and Related Sciences, Nantong University 1990
  • Doctor of Medicine, Soochow University 1987
  • Full Name

  • Zhi-Xiang Xu
  • Fax

  • 205-934-1870